Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionSumitomo Mitsui Trust Holdings, Inc.
Latest Disclosed Ownership220,449 shares
Latest Disclosed Value $ 29,041,951
Sumitomo Mitsui Trust Holdings, Inc. reports 8.77% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On April 30, 2026 - Sumitomo Mitsui Trust Holdings, Inc. filed a 13F-HR form disclosing ownership of 220,449 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $29,041,951 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 23, 2026 disclosing 202,666 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 8.77% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-30 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 220,449 17,783 8.77 29,042 1.03 0.0188
2026-01-23 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 202,666 -18,624 -8.42 28,744 -7.47 0.0169
2025-10-27 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 221,290 -14,198 -6.03 31,065 4.95 0.0179
2025-07-31 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 235,488 4,030 1.74 29,598 15.62 0.0184
2025-04-25 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 231,458 -1,399 -0.60 25,599 -19.46 0.0181
2025-01-28 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 232,857 916 0.39 31,785 18.93 0.0215
2024-11-05 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 231,941 -11,502 -4.72 26,724 -20.26 0.0185
2024-07-19 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 243,443 -9,122 -3.61 33,515 -3.79 0.0247
2024-04-19 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 252,565 8,630 3.54 34,834 8.38 0.0239
2024-01-30 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 243,935 12,382 5.35 32,141 23.38 0.0238
2023-10-30 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 231,553 -10,951 -4.52 26,050 13.91 0.0214
2023-07-31 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 242,504 -42,423 -14.89 22,868 -20.71 0.0178
2023-04-27 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 284,927 877 0.31 28,840 -14.99 0.0215
2023-01-30 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 284,050 -179 -0.06 33,927 12.38 0.0269
2022-10-21 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 284,229 1,189 0.42 30,188 9.41 0.0248
2022-07-26 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 283,040 3,122 1.12 27,591 5.14 0.0212
2022-04-27 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 279,918 -15,126 -5.13 26,242 4.43 0.0175
2022-02-02 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 295,044 30,585 11.57 25,129 -0.93 0.0153
2021-10-25 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 264,459 -5,727 -2.12 25,364 -3.54 0.0158
2021-08-02 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 270,186 -35,100 -11.50 26,295 -11.43 0.0155
2021-04-30 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 305,286 -1,208 -0.39 29,689 1.06 0.0186
2021-02-05 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 306,494 -32,227 -9.51 29,377 -9.81 0.0190
2020-10-30 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 338,721 -87,124 -20.46 32,571 -37.31 0.0219
2020-07-27 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 425,845 -127,819 -23.09 51,953 8.42 0.0367
2020-04-27 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 553,664 256,002 86.00 47,920 49.77 0.0412
2020-01-31 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 297,662 297,662 31,996 0.0252
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.